| Assessment Status | Assessment Process Complete |
| HTA ID | - |
| Drug | Prasugrel |
| Brand | Efient® |
| Indication | For the prevention of atherothrombotic events in patients with acute coronary syndrome undergoing primary or delayed percutaneous coronary intervention. |
| Assessment Process | |
| Full submission received from Applicant | 31/07/2009 |
| NCPE assessment completed | 01/02/2010 |
| NCPE assessment outcome | Reimbursement Recommended |
The review group consider that prasugrel, co-administered with aspirin, is cost-effective in patients with acute coronary syndrome undergoing primary or delayed percutaneous coronary intervention in the Irish healthcare setting.